Evidence map›Paper›PMID 30980197›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2019

Rivaroxaban in cervical and "cervico-cerebral" artery dissections: a new therapeutic option?

Giovanni Malferrari, Domenico Laterza, Franco Valzania, Daniela Monaco, Mauro Silingardi, Attilia Maria Pizzini

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Giovanni MalferrariDepartment of Neurology Unit, Azienda USL-IRCCS, Reggio Emilia, RE, Italy.
Domenico LaterzaDepartment of Neuroscience, St. Agostino Estense Hospital, University of Modena and Reggio Emilia, Modena, Italy. dome.laterza@live.it.
Franco ValzaniaDepartment of Neurology Unit, Azienda USL-IRCCS, Reggio Emilia, RE, Italy.
Daniela MonacoDepartment of Urgency and Emergency - Stroke Unit, S. Spirito Hospital, Pescara, PE, Italy.
Mauro SilingardiDepartment of Medicine, Maggiore Hospital, Bologna, BO, Italy.
Attilia Maria PizziniDepartment of Medicine, Maggiore Hospital, Bologna, BO, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITOspedale di Santo Spirito · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiplatelet agents and vitamin K antagonists (VKA) are usually used in the treatment of cervical (carotid or vertebral) artery dissections (CADs); however, data about the use of direct oral anticoagulants (DOACs) in these conditions are very limited. DOACs have proven to be effective in stroke reduction in non-valvular atrial fibrillation and, when possible, they are preferred to warfarin because of their better safety profile. We describe four cases of CADs and, firstly in literature, cervico-cerebral (CCADs) in young patients (average age of 42 years) treated with rivaroxaban 20 mg daily. Three of these four dissections had affected the vertebral artery (condition with an unfavorable prognosis and more often complicated by subarachnoid hemorrhages), and the other one was a carotid dissection at the extra-intracranial passage. All patients were followed clinically and with serial neurosonological examinations at 1, 3, and 6 months and with magnetic resonance angiography (MRA) at 6 months. All patients presented a good outcome with vascular recanalization without stroke recurrence or bleedings, even in patients with intracranial vertebral artery involvement. DOACs could be an alternative in young patients with CADs and their use could be considered in intracranial artery dissections too.

Indexed as

AdultCarotid Artery, Internal, DissectionFactor Xa InhibitorsFemaleHumansMaleMiddle AgedRivaroxabanStrokeVertebral Artery DissectionFactor Xa InhibitorsRivaroxabanCervical and cervico-cerebral artery dissectionsDOACsNeurosonologyRivaroxabanStrokeTranscranial color Doppler

Identifiers

PMID30980197
OpenAlexW2937459396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.